Endogenous Neurogenesis Replaces Oligodendrocytes and Astrocytes after Primate Spinal Cord Injury

Hong Yang, Paul Lu, Heather M. McKay, Tim Bernot, Hans Keirstead, Oswald Steward, Fred H. Gage, V. Reggie Edgerton, and Mark H. Tuszynski

Introduction
Spinal cord injury (SCI) frequently results in permanent loss of neurological function below the injury site, although humans with partial sparing of function after injury often exhibit substantial improvement over periods of weeks to months (Little and Halar, 1985; Roth et al., 1991; Nathan, 1994; Coleman and Geisler, 2004). Putative mechanisms of spontaneous recovery over time include both compensatory behavioral strategies to maximize use of spared systems (for review, see Barbeau et al., 2002) and potential anatomical mechanisms of axonal sprouting (Goldberger, 1974; Galea and Darian-Smith, 1997; Weidner et al., 2001; Barea and et al., 2004) or remyelination. Little is known, however, regarding the nature or extent of new cell division after SCI in mammals and about its potential to contribute to endogenous repair mechanisms.

Although few studies have examined endogenous stem-cell-like responses to SCI (McTigue et al., 2001), several reports describe therapeutic grafting of stem cells or lineage-restricted precursor cells to SCI sites (McDonald et al., 1999; Vroemen et al., 2003; Hill et al., 2004; Pfeifer et al., 2004). Some of these studies report functional recovery (McDonald et al., 1999; Pfeifer et al., 2004), with suggestions that grafted stem cells differentiate into glial cells, including astrocytes or oligodendrocytes. To date, however, no studies have examined new cell division after primate SCI and the potential of this mechanism to contribute to natural repair. Given the modest extent of natural recovery from mammalian SCI, this study explored the hypothesis that cell division after primate SCI is primarily limited to inflammatory cell lineages. Unexpectedly, we find extensive generation of new cells expressing mature markers of astrocytes and oligodendrocytes at extended time points after primate SCI.

Materials and Methods
Four adult male rhesus monkeys underwent right-sided cervical spinal cord transection lesions (Table 1); one intact monkey was also studied. Bromodeoxyuridine (BrdU) (50 mg · kg⁻³ · d⁻¹) was injected daily on each of the first 5 d after injury. After survival periods of 7 weeks to 7 months, the number and fate of newly dividing cells were quantified in the spinal cord. Double- and triple-confocal immunolabeling were used to colocalize BrdU with multiple cell-specific markers and to quantify cells using stereological methods.

Subjects. Five male rhesus monkeys were subjects of the study (mean age, 9.8 ± 1.56 years; range, 6–14 years of age). All animals were housed at the California National Primate Research Center, and animal care procedures adhered to the Association for Assessment and Accreditation of Laboratory Animal Care and institutional guidelines.

Spinal cord lesions. Monkeys were preanesthetized with 10 mg/kg ketamine intramuscularly, intubated, and anesthetized with 1.5–2.5% isoflurane. All responses to stimuli (eyelid flutter, forepaw pressure) were verifiably absent before proceeding with surgery. A dorsal laminectomy was performed from C5 to C7, and unilateral spinal cord lesions were placed as follows: subject 1 underwent a transection lesion of 30% of the left hemiscord at C7, sparing the most 2.5 mm of medial tissue. (The normal width of the spinal cord at this level is 8–10 mm.) Subject 2...
underwent a complete right-sided hemisection at C6. Subject 3 underwent a transection lesion of 50% of the left hemisected at C7, sparing the most 1.5 mm of medial tissue. Subject 4 underwent transection of 65% of the left hemisected at C6. (Various lesion sizes were performed as part of model development for future regeneration studies.) Lesion extent in each subject is shown in supplemental Figure 2 (available at www.jneurosci.org as supplemental material). Lesions were made under direct microscopic guidance using a #11 knife blade. After lesion completion, the overlying dura, muscle, and skin were separately sutured and closed. Antibiotics analgesics and supportive care were provided until subjects were able to move freely about the home cage (3–4 d). Bowel and bladder dysfunction did not occur. Postoperatively, subjects exhibited long-lasting paralysis of the arm on the affected side and transient paralysis of the leg. Spinal cords were then postfixed in 4% paraformaldehyde for 6–12 h and 10% glycerol with 4% paraformaldehyde in 0.1M phosphate buffer, pH 7.4, at 4°C. Cords were then dehydrated through a graded series of ethanol followed by 20% glycerol as the final fixative. Spinal cords were then embedded in an embedding film sheet (Electron Microscopy Sciences, Fort Washington, PA) and polymerized between 2.5 h. To specifically label mature oligodendrocytes, mouse anti-adenomatous polyposis coli (APC) monoclonal antibody (tumor suppressor gene product, clone CC1; 1:400; Oncogene Research Products, Cambridge, MA) was used (Bhat et al., 1996). Because APC also labels some astrocytes, BrdU/APC/GFAP triple labeling was used to clearly distinguish oligodendrocytes from astrocytes (McTigue et al., 2001): cells that were BrdU+/APC+/GFAP− were identified as oligodendrocytes. Myelin was labeled with mouse anti-myelin oligodendrocyte-specific protein monoclonal antibody (MOBP; 1:500; Chemicon). MOBP is a marker for central myelin and oligodendrocytes at a stage of development in which oligodendrocytes are elaborating processes and initiating myelin membrane sheet formation (Dyer and Matthieu, 1994). Axons were immunofluorescently labeled using rabbit anti-neurofilament 200 kDa (1:500; Chemicon). Apoptosis was detected using both Nissl and bisbenzimide (Hoechst 33342; Invitrogen) staining to assess nuclear fragmentation.

For electron microscopy, tissue sections were postfixed in 4% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 10 d, rinsed in 0.1 M cacodylate buffer, pH 7.4, for 30 min, postfixed in 0.5% OsO4 for 30 min, dehydrated in ascending alcohols, embedded in Spurr resin (Electron Microscopy Sciences, Fort Washington, PA), polymerized between 2.5 h. The thymidine analog BrdU was used to label proliferating cells after SCI. BrdU (50 mg/kg in sterile saline; Sigma, St. Louis, MO) was injected intravenously daily, for 5 consecutive days, beginning 1 d after lesion. Thus, the examined proliferative response focused on cell genesis occurring within several days of SCI in the primate.

**Table 1. Experimental subjects**

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Age (year)</th>
<th>Type</th>
<th>Lesion</th>
<th>Lesion volume</th>
<th>Lesion level</th>
<th>Lesion time</th>
<th>After lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.8</td>
<td>Subhemisection</td>
<td>14 mm³</td>
<td>C7</td>
<td>7 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>12.4</td>
<td>Hemisection</td>
<td>62 mm³</td>
<td>C6</td>
<td>9 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>8.2</td>
<td>Subhemisection</td>
<td>35 mm³</td>
<td>C7</td>
<td>15 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>8.5</td>
<td>Subhemisection</td>
<td>38 mm³</td>
<td>C6</td>
<td>29 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>14.2</td>
<td>Intact</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All subjects were male. N/A, Not applicable.

glial fibrillary acid protein (GFAP) polyclonal antibody (for astrocytes; 1:750; Dako, High Wycombe, UK); mouse anti-human p75 monoclonal antibody (low-affinity neurotrophin receptor, for Schwann cells; 1:100; a generous gift from Dr. Bothwell, University of Washington, Seattle, WA); rabbit anti-NG2 polyclonal antibody (chondroitin sulfate proteoglycan, for oligodendroglial precursor cells, Schwann cells, or macrophages; 1:500; a generous gift from Dr. Stallcup, The Burnham Institute, La Jolla, CA) and mouse anti-vaso-Willibrand factor (vWF) (for endothelia; Chemicon). For BrdU and NG2 double immunolabeling, antibody incubation was conducted before HCl treatment. Sections were developed using a mixture of Alexa 488-conjugated goat anti-58k IgG and Alexa 568-conjugated goat anti-rabbit or goat anti-mouse IgG (in TBS containing 3% normal goat serum and 0.25% Triton X-100; 1:200; Invitrogen) for 2.5 h. To specifically label mature oligodendrocytes, mouse anti-adenosomal polyposis coli (APC) monoclonal antibody (tumor suppressor gene product, clone CC1; 1:400; Oncogene Research Products, Cambridge, MA) was used (Bhat et al., 1996). Because APC also labels some astrocytes, BrdU/APC/GFAP triple labeling was used to clearly distinguish oligodendrocytes from astrocytes (McTigue et al., 2001): cells that were BrdU+/APC+/GFAP− were identified as oligodendrocytes.

To determine the fate of newly born cells after SCI, double-fluorescent immunolabeling was performed, combining BrdU labeling with one of the cell-specific phenotypic markers listed above. For double immunofluorescence, sections were pretreated with 2N HCl at 40°C for 30 min and rinsed in TBS, and nonspecific antigen binding was blocked in solution containing TBS, 5% normal goat serum, and 0.25% Triton X-100 (TBS + +) for 1 h. Sections were subsequently incubated in rat anti-BrdU (1:400 in TBS++; Serotech, Oxford, UK) at 4°C for 48 h. Sections were rinsed in TBS and incubated in Alexa 488-conjugated goat anti-58k IgG (in TBS containing 3% normal goat serum and 0.25% Triton X-100; 1:200; Invitrogen, Eugene, OR) for 2.5 h. After rinsing in TBS, sections were mounted onto slides, allowed to half-dry, and coverslipped using Fluoromount G (Southern Biotechnology, Birmingham, AL).

To determine the fate of newly born cells after SCI, double-fluorescent immunolabeling was performed, combining BrdU labeling with one of the cell-specific phenotypic markers listed above. For double immunofluorescence, sections were pretreated with HCl as described above and incubated with BrdU antibody mixture with one of the following antibodies in TBS++ at 4°C for 48 h: mouse anti-neuron-specific nuclear protein (NeuN) monoclonal antibody (vertebrate neuron-specific nuclear protein, for neurons; 1:250; Chemicon, Temecula, CA), mouse anti-MAP2 (microtubule-associated protein 2) monoclonal antibody (for neurons; 1:10,000, Chemicon); mouse anti-β-III-tubulin monoclonal antibody, (tubulin, β III isof orm, for neurons; 1:750; Chemicon); rabbit anti-IBA1 polyclonal antibody (ionizing calcium-binding adapter molecule, for macrophages and microglia; 1:1000; generous gift from Dr. Imai, National Institution of Neuroscience, Tokyo, Japan); rabbit anti-
Cardiovascular system

Because of the large number of phenotypic markers examined in this study (nine cell-specific labels per monkey, in addition to BrdU label and Nissl stain), there were not sufficient numbers of sections to conduct a stereological quantification for each label. Reliable estimates of the distribution of proportionate cell populations can however be derived by a sampling a total of ~200 cells per phenotypic label, using random sampling schemes and the exclusion zones used by the stereology software program (StereoInvestigator) (Peterson, 1999). We used this method in the present study to identify the proportion of BrdU-labeled cells expressing each phenotype-specific marker. Thus, for each double label of BrdU with a cell-specific marker, a minimum of 200 BrdU+ cells was counted in each of the three quantified regions (perilesion region, intact gray, intact white) in each subject, using confocal microscopy (Olympus Fluoview) and random sampling of fields at 400× magnification. The specificity of each label was first verified using single-channel scans that were then merged into multiple-channel views. To confirm double-labelling, confocal Z-stacks were generated. For quantification, sections were digitally scanned using 488 and 568 dual-laser channels. BrdU single-labeled cells, and cells double labeled for BrdU and another specific marker, were recorded. For mature oligodendrocytes, 488, 568, and 647 triple-laser channels were used. Results for each marker are presented as the proportion of all BrdU+ cells per region that are double labeled for BrdU and the label of interest. Two sections per animal were sampled from the immediate injury vicinity. Phenotypic analysis and quantification was performed at the C6 level in one intact monkey using methods described above. Oligodendrocytes in the lumbar corticospinal tract region were quantified in two sections per animal at 600× magnification, comparing lesioned and nonlesioned sides of the cord.

**Imaging and statistical analysis.** Images were processed using Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA) or Volocity 3.0 (Improvisio, Lexington, MA). To assess differences in the number of BrdU-labeled cells in various regions of the injured spinal cord (Fig. 1), ANOVA was used with a criterion of p < 0.05 for significance.

**Results**

**Cell division after SCI**

SCI resulted in the recruitment of vast numbers of newly dividing cells to the perilesioned region of the spinal cord (Fig. 1): a mean of 19,500 ± 3900 BrdU-labeled cells/mm³ (± SEM) was present in the lesioned region, an 81-fold increase compared with the number of BrdU-labeled cells at C6 in the intact monkey (240 cells/mm³). The greatest number of cells, determined stereologically, was present in the subject with the largest lesion (Fig. 1E). Numbers of newly dividing cells were also increased in gray matter (5000 ± 2300 BrdU-labeled cells/mm³) and white matter (1500 ± 500 BrdU-labeled cells/mm³) contralateral to the lesion at C6–C7 among all subjects, compared with the intact animal (Fig. 1E). In the lumbar spinal cord ipsilateral to the cervical lesion, located several segments away from the lesion, numbers of newly dividing cells were also substantially increased to a mean 3900 ± 1400 cells/mm³ in contrast to 290 BrdU-labeled cells/mm³ in the lumbar region of the intact subject. Most of the BrdU-labeled cells in the lumbar cord were present in tracts that contained descending, anterogradely degenerated axons, whereas relatively few BrdU-labeled cells were present in tracts containing
rostrally projecting axons (e.g., the dorsal columns). Hence, BrdU labeling vastly increases adjacent to and remote from primate spinal cord lesion sites. The mean volume of the spinal cord perilesioned region was $37.1 \pm 10.3$ mm$^3$ in the four lesioned subjects; thus, a calculated mean of 725,000 newly dividing cells per monkey were generated as a result of SCI in the immediate injury zone.

**Identities of newly dividing cells**

The identities of newly dividing cells varied as a function of time after injury (Fig. 2). In all cases, cellular double labeling was verified by thin-plane confocal microscopy in $xy$, $xz$, and $yz$ planes. Within the perilesion region at the earliest time point of 7 weeks after injury, inflammatory cells comprised the majority of BrdU-labeled cells, with 81% of BrdU-containing cells coexpressing the macrophage/microglial marker IBA (Figs. 2, 3). The proportion of IBA-labeled cells gradually declined to 18% of all BrdU-labeled cells by 7 months after injury, and most IBA-labeled cells at this time point exhibited morphological features of resting microglia (Fig. 3). A similar evolution of labeling was observed in contralateral, intact regions of the spinal cord (Table 2).

In contrast to the successive reduction over time in the proportion of BrdU-labeled cells expressing inflammatory-related markers after injury, the proportion of newly divided cells expressing mature oligodendrocyte and astrocyte markers sequentially increased from 7 weeks to 7 months after injury (Figs. 2, 4). To identify oligodendrocytes, sections were triple labeled for BrdU, APC (astrocytes/oligodendrocytes), and GFAP (astrocytes) (Fig. 4); cells that were BrdU positive/APC positive/GFAP negative (BrdU+/APC+/GFAP−) were identified as oligodendrocytes (McTigue et al., 2001). Although only 4% of BrdU-labeled cells in the perilesion region exhibited markers of oligodendrocyte differentiation at 7 weeks after injury, the proportion of BrdU-labeled cells expressing mature oligodendrocyte markers increased to 15% by 7 months after injury (Figs. 2, 4). Parallel changes were observed in the contralateral, intact regions of the cord (Table 2). Electron microscopy indicated that spinal cord

---

**Table 2. Percentage of BrdU-labeled cells that express specific phenotypic markers on intact side of primate spinal cord, contralateral to lesion**

<table>
<thead>
<tr>
<th>Markers</th>
<th>Subject 1</th>
<th></th>
<th>Subject 2</th>
<th></th>
<th>Subject 3</th>
<th></th>
<th>Subject 4</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IG</td>
<td>IW</td>
<td>IG</td>
<td>IW</td>
<td>IG</td>
<td>IW</td>
<td>IG</td>
<td>IW</td>
</tr>
<tr>
<td>IBA</td>
<td>89 ± 3%</td>
<td>77 ± 14%</td>
<td>85 ± 4%</td>
<td>90 ± 12%</td>
<td>60 ± 0.3%</td>
<td>15 ± 0.7%</td>
<td>58 ± 6%</td>
<td>57 ± 7%</td>
</tr>
<tr>
<td>vWF</td>
<td>9 ± 2%</td>
<td>10 ± 1%</td>
<td>10 ± 2%</td>
<td>6 ± 0.3%</td>
<td>12 ± 0.8%</td>
<td>13 ± 1%</td>
<td>16 ± 3%</td>
<td>12 ± 0.9%</td>
</tr>
<tr>
<td>APC</td>
<td>0.4 ± 0.1%</td>
<td>0.5 ± 0.7%</td>
<td>0.3 ± 0.3%</td>
<td>0.3 ± 0.2%</td>
<td>0</td>
<td>0</td>
<td>13 ± 3%</td>
<td>11 ± 1%</td>
</tr>
<tr>
<td>GFAP</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3 ± 0%</td>
<td>2 ± 0.7%</td>
</tr>
</tbody>
</table>

IG, Gray matter; IW, white matter. Values are mean ± SEM. Note: Totals are <100% because not all BrdU-labeled cells express the markers indicated above.
segments surrounding the lesion site exhibited both demyelination and remyelination (Fig. 5). To ensure that oligodendrocyte remyelination could reliably be distinguished from normal myelination, we analyzed G-ratios (the ratio between the thickness of the myelin sheath and the diameter of the axon) for normally myelinated or oligodendrocyte-remyelinated axons. Oligodendrocyte-remyelinated axons were identified by their characteristically thin myelin sheaths relative to the diameter of the axons (Hildebrand and Hahn, 1978; Guy et al., 1989). Myelin sheath thickness in axons remyelinated by oligodendrocytes did not reach the thickness observed in normally myelinated axons. The mean G-ratio of oligodendrocyte-remyelinated axons, 5.32 ± 1.3 (16), was significantly less than the mean G-ratio of normally myelinated axons, 46.4 ± 28.3 (15) (p < 0.01; data are expressed as mean ± SD; numbers in parentheses indicate the number of axons scored). Thin-plane confocal imaging indicated that APC-labeled extensions of BrdU-labeled cells in the perilesion region appeared to surround and ensheathe axons (Fig. 5); many BrdU-labeled cells in these regions also exhibited colocalization of APC with myelin markers such as MOSP (Fig. 5A–C). These observa-

**Figure 4.** BrdU colocalization with mature oligodendrocyte markers. A, BrdU colocalizes with mature oligodendrocyte marker APC in perilesion region 7 months after injury; blue arrows indicate double-labeled cells, orange arrowheads indicate single BrdU-labeled cells. GFAP (white) is not colocalized with these cells. B, A BrdU/APC double-labeled cell from the C6 spinal cord contralateral to the lesion, exhibiting a long APC-labeled process (arrowheads) emanating from the cell body, indicating extension of APC label into myelinating segment of cell. C, BrdU/APC double-labeled cell (blue arrow) and BrdU/GFAP double-labeled cell (orange arrowhead) in perilesion region. D, Confocal Z-stacks of BrdU/APC double-labeled cells; 1 μm separation. E, xy, xz, and yz planes showing colocalization of BrdU with mature oligodendrocyte marker. Scale bars: A, 15 μm; B, 5 μm; C–E, 10 μm.
tions suggest that a proportion of newly dividing cells after primate SCI exhibit anatomical and immunocytochemical characteristics of functional oligodendrocytes.

The proportion of BrdU-labeled cells expressing markers of mature astrocytes increased from 2% at 7 weeks after injury to 12% by 7 months after injury in the perilesion region, with parallel changes in the contralateral, intact regions (Figs. 2, 6, Table 2). Hence, new cell division repopulates glial cells around the injury site after primate SCI.

Oligodendrocyte cell death occurs at spinal levels remote from injury sites via apoptotic mechanisms (Crowe et al., 1997). Consistent with this finding, we observed fragmented cell nuclei in the lumbar spinal cord, remote from the lesion site, by both Nissl and Hoechst staining (supplemental Fig. 1, available at www.

---

**Figure 5.** Demyelination and remyelination after primate SCI. **A**, Electron photomicrograph of a remyelinated axon (RA) with a characteristically thin myelin sheath within ventrolateral white matter 2.5 mm caudal from lesion epicenter. An abundance of hypertrophic intermediate filament-rich astrocytic processes (As) surround the remyelinated axon. Scale bar, 0.5 μm. **B–D**, Triple labeling for APC, neurofilament (NF), and MOSP (labels oligodendrocytes and CNS myelin but not peripheral myelin). **B**, APC and MOSP labeling are evident surrounding NF-labeled axons in perilesion region, indicating that APC labeling can identify myelin around axons in lesioned regions. **C**, Images from unlesioned contralateral white matter show individual NF-labeled axons within MOSP-labeled myelin sheaths (arrowheads). **D**, APC (arrowheads) colocalizes with MOSP, indicating that APC labeling under high-resolution confocal microscopy can colocalize within rings of myelin that surround individual axons. **E**, An NF-labeled axon is surrounded by APC immunolabeling, suggesting ensheathment or myelination by an oligodendrocyte in the contralateral, intact region of the spinal cord. **F**, Z-stack of a BrdU/APC double-labeled oligodendrocyte in longitudinal plane, showing an NF-labeled axon ensheathed by this cell (arrow) and, in subsequent z-sections, the same cell showing continuity of APC-labeling with a BrdU-labeled nucleus (within square). Each image is 0.5 μm thick, and images span a total range of 7.0 μm. Thus, newly born cells after primate SCI express markers associated with mature oligodendrocytes and appear to ensheath or myelinate axons. An oligodendrocyte nucleus of an adjacent cell, also BrdU labeled, is indicated by the arrowhead. Scale bars: **B–F**, 10 μm.
active or recent cell division. Labeled nuclei are colocalized with cytoplasmic GFAP in perilesion region. Juxtaposition of nuclei and cytoplasm may indicate spindle-shaped morphology of Schwann cells (Fig. 7). Many of these p75-expressing, spindle-shaped cells colocalized with BrdU, indicating that Schwann cells divide and migrate into the lesion site. Colocalization of BrdU with the endothelial cell marker vWF suggests that vascular cells also proliferate after SCI (Fig. 7).

Cell division in the intact animal
A total of 240 BrdU-labeled cells/mm³ were detected at the C6 level of the spinal cord in one intact monkey 18 weeks after BrdU injection. Phenotypic analysis revealed that 44% of BrdU-labeled cells in this animal expressed the microglial marker IBA, and 41% of cells expressed the vascular marker vWF. Cells double labeled for oligodendrocytes and astrocytes were rare, constituting <1% of all BrdU-labeled cells in the intact spinal cord. Neither Schwann cells nor NG2 expressing cells were detected in this subject. Remaining BrdU-labeled cells (~14%) did not colocalize with any of the phenotypic markers used in this study.

Discussion
These findings reveal that robust endogenous cell division occurs after primate SCI. There are two long-term consequences of this spontaneous cell division: (1) a subpopulation of newly dividing cells adopt mature oligodendrocyte markers in regions of demyelination, appearing to ensheathe or remyelinate axons, and (2) new astrocytes are generated, a phenomenon that is likely to be important for reestablishing parenchymal stability and the blood–brain barrier after injury (Sofroniew, 2000; Faulkner et al., 2004). Of note, primate SCI does not result in new neuron formation derived from cells dividing within 5 d of injury. These findings reveal previously unknown endogenous mechanisms for glial replacement after primate SCI that may reduce outcome severity, particularly after incomplete injury.

The major findings of this study are based on the examination of four lesioned subjects, all males, who received lesions of the right side of the spinal cord. Lesion volume was varied between subjects, and survival times ranged from 7 weeks to 7 months after injury. Yet, findings were highly consistent between subjects; that is, the proportion of BrdU-labeled cells colocalizing with inflammatory markers consistently and steadily diminished from 7 weeks to 7 months after injury, whereas the proportion of BrdU-labeled cells colocalizing with astrocytic, oligodendrocyte, and Schwann cell markers consistently and steadily increased around the lesion site over the same time period. Variability of the data were minimized by use of stereological quantification of BrdU cell numbers and random and corrected sampling methods for determination of the phenotype of BrdU-labeled cells. Thus, differences in lesion size between subjects were accounted for in the analyses we used, and larger lesions appeared to increase the total number but not the phenotypic fate of BrdU-labeled cells.

There is a decrease in the density of BrdU-labeled cells (in cells per cubic millimeter) in the perilesioned region from 7 weeks (28,700/mm³) to 7 months (14,100/mm³) after lesion (calculated from data in Fig. 1E). This decrease of BrdU cell density is likely attributable to the clearing of BrdU-labeled inflammatory cells from the perilesioned region, although it may also partially

Figure 6. Newly born astrocytes at sites of SCI. A, BrdU/GFAP double-labeled astrocytes in perilesion region (arrows) 9 weeks after injury. B, 2-stack of BrdU/GFAP double-labeled astrocyte indicates cellular colocalization; 1 μm separation. C, Two BrdU-labeled nuclei are colocalized with cytoplasmic GFAP in perilesion region. Juxtaposition of nuclei and cytoplasm may indicate active or recent cell division. D, xy, xz, and yz views of the BrdU/GFAP double-labeled astrocyte, as shown in B. Scale bars: A, 15 μm; B, C, 5 μm.
result from dilution of BrdU below limits of detection after several cycles of cell division. Whereas the density of BrdU-labeled inflammatory cells diminishes at progressive time points after injury, the percentage of oligodendrocytes and astrocytes increases. This proportionate increase in newly generated glia could be caused either by the clearing of BrdU-labeled inflammatory cells or to continued maturation of glia over very extended time periods after injury. Calculation of the density of BrdU-labeled glial cells per cubic millimeter in perilesioned tissue at successive time points after injury (calculated from data in Fig. 1E) reflects no distinct trend toward a continuing increase in either BrdU-labeled oligodendrocytes or astrocytes after injury, tentatively suggesting that most glial genesis may be established by 7 weeks after injury. However, additional studies would be required to clearly address this point.

The pattern of recovery from injury to the brains and spinal cords of nonhuman primates parallels, in some respects, observations in humans: complete or extensive lesions of a system are rarely followed by substantial functional recovery, whereas partial lesions are often accompanied by a substantial degree of functional recovery (Turner, 1891; Mott, 1892; Mettler, 1944; Lassek and Anderson, 1961; Kuypers, 1974; Schwartzman, 1978; Little and Halar, 1985; Roth et al., 1991; Nathan, 1994; Coleman and Geisler, 2004) that is paralleled by systems-level plasticity (Netz and Homberg, 1997; Marshall et al., 2000; Schmidlin et al., 2004). Partial lesions that spare some pathways provide a potential substrate for subsequent spontaneous plasticity in the form of sprouting of spared axons or modified use of spared projections, which could lead to functional improvement. In the case of SCI, a component of the functional deficit after injury is thought to be attributable to demyelination of spared axons (Griffiths and McCulloch, 1983; Waxman, 1992; Bunge et al., 1994; Cao et al., 2001), and the present findings suggest that remyelination of spared projections by newly generated oligodendrocytes could...
contribute to recovery. Previous studies suggest that embryonic stem cells, when implanted into the spinal cord, differentiate into oligodendrocytes and remyelinate host axons (Keirstead et al., 2005). Our findings indicate that the injured spinal cord environment could facilitate stem cell differentiation along glial lineages. A preference for glial differentiation has also been reported in the few studies examining cell division in the intact adult rodent spinal cord: newly dividing cells in the intact rodent spinal cord adopt glial but not neuronal fates (Horner et al., 2000) and, indeed, cues in the intact spinal cord appear to specifically favor glial rather than neuronal cell-type differentiation (Shihabuddin et al., 2000; Song et al., 2002). In addition to a potential role of oligodendrocyte differentiation in supporting recovery after primate SCI, astrocytic differentiation observed in this study could also contribute to recovery. Immature astrocytes facilitate axon outgrowth (Smith et al., 1990) and recovery of the CNS from injury requires astrocyte activation (Sofroniew, 2000; Faulkner et al., 2004; Smith et al., 1990). In agreement with the present findings, a previous study also reported extensive glial differentiation (Zai and Wrathall, 2005) of newly born cells after contusive SCI in rats.

This study demonstrates that newly divided cells within 5 d of injury are abundant near sites of primate SCI and that the long-term fate of many of these cells is to repopulate glia. It is possible that experimental augmentation of endogenous stem cell responses could increase recovery after SCI. For example, a recent report in a rodent model indicated that Neurogenin-2 exposure increased neuronal differentiation by stem cells (Hofstetter et al., 2005), raising the possibility of neuronal replacement at sites of SCI. Future experimental approaches could attempt to increase the number and modify the fate of differentiating endogenous stem cells.

References